Articles from Caixin Global, Caixin Global

Caixin Global

Articles from Caixin Global

Caixin is a media group dedicated to providing financial and business news through periodicals, online content, mobile apps, conferences, books and TV/video programs. Caixin aims to blaze a trail that helps traditional media prosper in the new media age through integrated multimedia platforms.

News from Caixin

Thematic (Sector/Industry)

<ul>
<li>After years of falling valuations and stalled IPO activity, China’s innovative drug industry is showing early signs of a comeback.</li>
<li>A spate of large-scale cross-border licensing deals is rekindling global interest and lifting stock prices, suggesting a possible shift in momentum for the sector.</li>
<li>Yet despite headline-grabbing transactions and the buoyant market response, industry veterans warn the rebound may be selective, with persistent challenges still clouding the sector’s long-term outlook.</li>
</ul>


After years of falling valuations and stalled IPO activity, China’s innovative drug industry is showing early signs of a comeback.
A spate of large-scale cross-border licensing deals is rekindling global interest and lifting stock prices, suggesting a possible shift in momentum for the sector.
Yet despite headline-grabbing transactions and the buoyant market response, industry veterans warn the rebound may be selective, with persistent challenges still clouding the sector’s long-term outlook.


Chinese Biotech Innovators Push Overseas as Sector Faces Reckoning 

Cross Asset Strategy

<ul><li>Drugs / Cover Story: Chinese biotech is having a ‘deepseek moment’</li><li>Hong Kong /: Hong Kong bets on stablecoins and AI to future-proof its financial edge</li><li>Home appliances /Analysis: New U.S. tariffs mean tough times ahead for appliance-makers</li></ul>

Drugs / Cover Story: Chinese biotech is having a ‘deepseek moment’Hong Kong /: Hong Kong bets on stablecoins and AI to future-proof its financial edgeHome appliances /Analysis: New U.S. tariffs mean tough times ahead for appliance-makers

CX Daily: Chinese Biotech Is Having a ‘DeepSeek Moment’ 

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>3SBio entered into an exclusive licensing agreement with Pfizer granting them exclusive license to develop, manufacture, commercialize, and otherwise exploit its breakthrough PD-1/VEGF bispecific antibody SSGJ-707 worldwide excluding mainland China.</li>
<li>CSPC Pharmaceutical Group Limited announced that CPO301, their first-in-class epidermal growth factor receptor (‘‘EGFR’’) antibody drug conjugate (ADC), has been granted the third Fast Track designation by the U.S. FDA.</li>
<li>Samsung Biologics Co. announced that it plans to spin off its biosimilar development business into separate new entity, Samsung Epis Holdings. Samsung Biologics will become a pure-play CDMO.</li>
</ul>


3SBio entered into an exclusive licensing agreement with Pfizer granting them exclusive license to develop, manufacture, commercialize, and otherwise exploit its breakthrough PD-1/VEGF bispecific antibody SSGJ-707 worldwide excluding mainland China.
CSPC Pharmaceutical Group Limited announced that CPO301, their first-in-class epidermal growth factor receptor (‘‘EGFR’’) antibody drug conjugate (ADC), has been granted the third Fast Track designation by the U.S. FDA.
Samsung Biologics Co. announced that it plans to spin off its biosimilar development business into separate new entity, Samsung Epis Holdings. Samsung Biologics will become a pure-play CDMO.


APAC Healthcare Weekly (May 25)- 3SBio, Samsung Biologics, Celltrion, CSPC Pharma, Chugai

Podcast of business and financial stories, Behind the Money

Behind the Money

Podcast of business and financial stories

From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the business and financial stories of the moment with reporting from Financial Times journalists around the world.

<ul><li>Westport in County Meal, Ireland is a lively town with traditional pubs and a scenic backdrop of Croagh Patrick mountain.</li><li>The town benefits from American pharmaceutical companies like Allergan manufacturing products such as Botox, thanks to Ireland's low corporate tax rates.</li><li>However, President Trump's desire to bring back manufacturing to the US poses a threat to Ireland's economy and its relationship with multinational companies.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.</em></p>

Westport in County Meal, Ireland is a lively town with traditional pubs and a scenic backdrop of Croagh Patrick mountain.The town benefits from American pharmaceutical companies like Allergan manufacturing products such as Botox, thanks to Ireland's low corporate tax rates.However, President Trump's desire to bring back manufacturing to the US poses a threat to Ireland's economy and its relationship with multinational companies.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

How Trump’s tariffs threaten Ireland’s pharma fortune

<ul>
<li>EMA’s human medicines committee (CHMP) recommended sixteen medicines for approval at its April 2025 meeting. CHMP also adopted positive opinion for nine biosimilar medicines.</li>
<li>Among the new medicines, Vertex’s triple combination cystic fibrosis drug Alyftrek, Amgen’s Thyroid eye disease drug Tepezza, and Jazz Pharmaceutical’s billiary tract cancer drug Ziihera have potential to become blockbusters.</li>
<li>The Agency has recommended the refusal of the marketing authorization for Eli Lilly’s Alzheimer’s Disease drug Kisunla. Eli Lilly may ask for a re-examination of the opinion within 15 days.</li>
</ul>


EMA’s human medicines committee (CHMP) recommended sixteen medicines for approval at its April 2025 meeting. CHMP also adopted positive opinion for nine biosimilar medicines.
Among the new medicines, Vertex’s triple combination cystic fibrosis drug Alyftrek, Amgen’s Thyroid eye disease drug Tepezza, and Jazz Pharmaceutical’s billiary tract cancer drug Ziihera have potential to become blockbusters.
The Agency has recommended the refusal of the marketing authorization for Eli Lilly’s Alzheimer’s Disease drug Kisunla. Eli Lilly may ask for a re-examination of the opinion within 15 days.


CHMP Meeting Update April 2025: Sixteen New Medicines Recommended For Approval

United States

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pfizer (PFE UN)

Chinese Biotech Innovators Push Overseas as Sector Faces Reckoning

After years of falling valuations and stalled IPO activity, China’s innovative drug industry is showing early signs of a comeback. A spate of...

Caixin Global

CX Daily: Chinese Biotech Is Having a ‘DeepSeek Moment’

Drugs / Cover Story: Chinese biotech is having a ‘deepseek moment’ Hong Kong /: Hong Kong bets on stablecoins and AI to future-proof its financial...

Caixin Global

APAC Healthcare Weekly (May 25)- 3SBio, Samsung Biologics, Celltrion, CSPC Pharma, Chugai

APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...

Tina Banerjee

How Trump’s tariffs threaten Ireland’s pharma fortune

Westport, County Mayo in Ireland, known for traditional bars and lively atmosphere, faces uncertainty as President Trump's threats to bring...

Behind the Money

CHMP Meeting Update April 2025: Sixteen New Medicines Recommended For Approval

Among the new medicines, Vertex’s triple combination CF drug Alyftrek, Amgen’s Thyroid eye disease drug Tepezza, and Jazz Pharmaceutical’s cancer...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)